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The purpose of this review is to provide a general overview of ad-
juvants as immune potentiators, and to offer new insights into the 
immunological basis and molecular mechanisms of their action. Adju-
vants are a key component of many vaccines and their use and devel-
opment enables many avenues of vaccine design that would otherwise 
be impossible. Nevertheless, adjuvants are often associated with many 
safety concerns. Search of available medical literature on adjuvants, 
vaccines, and their mechanisms of action was performed. Additional 
articles were identified based on citations in retrieved articles. The 
main role of adjuvants is to trick the immune system in perceiving 
vaccine antigen as a serious threat, and thus initiate innate and consec-
utively adaptive response mechanisms, including long-term immune 
memory to that antigen. Adjuvants do that by triggering the same 
evolutionary conserved mechanisms that innate immunity utilizes to 
detect danger. By inducing innate immune reaction, adjuvants can 
concurrently provoke some undesirable immune response. However, 
serious adverse reactions to adjuvanted (as well as nonadjuvanted) vac-
cines are extremely rare, and there are carefully elaborated regulatory 
mechanisms to ensure that risks of such adverse reactions are kept at 
minimum. Conclusion. The use of adjuvants allows a great variety 
of vaccine designs, enabling the development of safer, more effective, 
more optimized, and more accessible vaccines than it would be pos-
sible without adjuvants. Despite frequent calls to debate, all currently 
used adjuvanted vaccines have repeatedly demonstrated an excellent 
safety profile and remain one of the principal tools of science-based 
medicine in preventing infectious diseases.
Introduction
Since the development of toxoid vaccines in 
the early 20th century, scientists were search-
ing for a way to enhance immunogenicity 
of non-living vaccines (1). Some of the first 
adjuvants discovered back then, on empiri-
cal basis of trial and error, are still in wide-
spread use today, but only recently some light 
on the molecular mechanisms of their action 
has been shed. Now, with the ever-growing 
knowledge of vaccine and adjuvant immu-
nology and technology, not only that we 
have deeper understanding of mechanisms of 
immune potentiation, but it is possible to ra-
tionally design a vaccine/adjuvant to improve 
the effectiveness, safety and manufacturing 
process of vaccines, and to tailor a desired re-
sponse to a vaccine to fit the specific need of 




The purpose of this review is to present 
to the readership with a general overview of 
adjuvants as immune potentiators, and to of-
fer new insights into the immunological basis 
and molecular mechanisms of their action. 
Since there is some controversy about the 
safety of adjuvanted vaccines and their im-
plication in the development of autoimmune 
diseases, the last section will address this issue.
Why we need adjuvants
The essence of active immunization (vacci-
nation) is acquiring long-lasting immunity 
to a pathogen without getting the disease. 
The best way to achieve that is to simulate 
natural infection but with a weakened, at-
tenuated, form of the pathogen (3). How-
ever, this is not always possible or practical 
to do in a convenient and safe way. Cultiva-
tion and production of live microorganisms 
is expensive, requires manipulation with 
potentially dangerous infectious agents, and 
there is always a possibility of spontaneous 
reversal to pathogenic form, resulting in a 
vaccine-associated disease of the host. In such 
cases, the dead pathogen is used, as a whole 
organism, or some of its key antigenic sub-
units. However, since dead organisms or their 
parts can obviously cause no infection, they 
may not induce a strong immune response. 
Hence such preparations are often not suffi-
ciently immunogenic, i.e., they do not confer 
adequate and long-lasting immunity to the 
pathogen. Adjuvants (from Latin adjuvare – 
to help) are therefore coadministered to en-
hance the immunogenicity of the vaccine an-
tigen. To achieve that, a good adjuvant needs 
to trick the immune system to perceive the 
vaccine antigen as a serious threat, and thus 
initiate innate and consecutively adaptive re-
sponse mechanisms to eliminate the threat 
and prepare itself (through long-term im-
mune memory) for the next encounter with 
the same threat (4).
Some inactivated whole-pathogen vac-
cines do not need an adjuvant since they 
contain a heterogeneous mixture of diverse 
antigens and other components of the patho-
gen that act as intrinsic adjuvants. Also, car-
bohydrate antigens do not need an adjuvant, 
as they directly bind to and activate B cells 
(T-cell-independent activation) (5). How-
ever, this type of humoral response is inher-
ently weaker, and, more importantly, of short 
duration, with no affinity matura tion and 
no immunological memory. For that reason, 
conjugate vaccines were developed, consist-
ing of carbohy drates conjugated to a protein 
that provides T cell epitopes for a T-cell-de-
pendent response needed for antibody class 
switching, affinity maturation, and long-
term immunological memory. Some of the 
protein components of conjugate vaccines 
can also have adjuvant capacity (6).
Practical goals of using adjuvants include: 
increasing the functional titer of antibodies 
raised against the target antigen; decreasing 
the dose of antigen needed to elicit immune 
reaction (antigen sparing); decreasing the 
number of doses needed to achieve complete 
immunization (dose reduction); enhancing 
immune responses in the young, elderly and 
immunocompromised populations (poor re-
sponders); increasing the duration of the vac-
cine-specific protective response; decreasing 
the time needed to achieve protective immu-
nity; induction of potent cell-mediated im-
munity; balancing or redirecting the immune 
response toward the Th1, Th2, or Th17 arm 
of the T cell response, as required; inducing 
mucosal immunity; and inducing a broader 
immune response (cross-protection against 
related strains of pathogen not included in 
the vaccine) (7, 8). In addition to achieving 
quantitative and qualitative alterations of the 
immune response, some of these goals, like 
antigen sparing and dose reduction, have 
important implications for improving global 
vaccine supply. Furthermore, by ensuring 
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enough immunogenicity to limited number 
of purified antigens in subunit vaccines, ad-
juvants contribute to general safety profile of 
the vaccines (9). In view of the above, it is 
easy to see why adjuvants are a key compo-
nent of many vaccines, as well as how their 
continuing use and development enables 
many avenues of vaccine design that would 
otherwise be completely impossible.
How adjuvants work
In 1926, French veterinarian Gaston Ramon 
reported that by injecting starch, bread-
crumbs, or tapioca, he managed to induce 
sterile abscesses at the site of injection with 
an inactivated toxin, which led to increased 
anti-sera production, confirming the hy-
pothesis that substances able to induce lo-
cal inflammation at the injection site were 
also able to enhance anti-sera yield (1). A 
few years later, British scientist Alexander 
Glenny discovered the immune-enhancing 
effects of aluminium salts (8). Aluminium 
was first used in human vaccines in 1932 
and remained the only adjuvant in use in li-
censed human vaccines for approximately 70 
years. Those and other early adjuvants have 
all been empirically identified for their ability 
to enhance the adaptive immune responses 
to a coadministered antigen in experimental 
models, and their mechanisms of action have 
long been “the immunologist’s dirty little se-
cret” (10). 
With the growing understanding of in-
nate immune system and its role in activa-
tion and modulation of adaptive immune 
response, the mechanisms of action of adju-
vants are also being unveiled.
The signals of danger
The key event in the immune response is de-
tecting an antigen in the context of danger. 
The concept of danger, i.e., specific compo-
nents of damaged host tissues (damaged self ) 
as primary signals for activation of protective 
immunity, as opposed to foreign or non-self 
structures, was proposed by Polly Matzinger 
in 1994 (11). Now it is recognized that these 
are not conflicting, but rather complemen-
tary hypotheses. Innate immune system, 
through a variety of conserved germline-
encoded innate receptors, recognizes specific 
molecular patterns of both exogenous and 
endogenous origin (12). Components of bac-
terial or fungal wall, or bacterial and viral nu-
cleic acids, represent examples of pathogen-
associated molecular patterns (PAMP). On 
the other hand, cellular components exposed 
during cell damage, like adenosine triphos-
phate (ATP), uric acid, and high mobility 
group box 1 (HMGB1), represent endog-
enous damage-associated molecular patterns 
(DAMP). Sensing danger is the initial step 
in the activation of innate immunity, and in-
nate immune reaction is the prerequisite for 
the activation of adaptive immunity and gen-
eration of an immunological memory.
Innate receptors
The most abundant and diverse innate recep-
tors are pattern-recognition receptors (PRR), 
which comprise Toll-like receptors (TLR), 
nucleotide oligomerization domain (NOD)-
like receptors (NLR), and the retinoic ac-
id-inducible gene-I (RIG-I)-like receptors 
(RLR) (12, 13). Each type of PRR has spe-
cific ligand(s) and specific signaling pathway. 
They are strategically located inside the cell or 
on its surface, depending on the accessibility 
of their ligands. Ligation of the PRR initiates 
a signaling network in host cells that regu-
lates transcription of pro-inflammatory genes 
and coordinates an appropriate immune re-
sponse to respond to the detected threat.
The best studied of the PRR are TLR. 
Originally discovered for its contribution to 
dorso-ventral patterning in Drosophila (fruit 
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fly) embryos, Toll molecule is later recognized 
for its role in the fly’s innate immune re-
sponse to microbial infection (14). There are 
10 types of its analogues in humans (TLR1 
to TLR10), and much more in other verte-
brates (23 different TLR in total), and each 
of them has specificity for different PAMP. 
Ligands for TLR include many microbial 
products, such as lipopolysaccharide (LPS) 
of Gram-negative bacteria, double-stranded 
(ds) RNA present in certain viruses, virus-
specific single-stranded (ss)RNA sequences, 
unmethylated CpG oligonucleotides derived 
from frequently found motifs in bacterial 
DNA, flagellin (a bacterial protein), mannan 
and related compounds of fungal cell walls, 
and glycophosphoinositol (GPI) anchors of 
protozoal cell membranes, to name but a few.
NOD-like receptors, such as NLRP3 
and NLRP4, upon ligation, form proteo-
lytic complexes called inflammasomes, which 
cleave the inactive form of pro-inflammatory 
cytokines IL-1, IL-18 and IL-33 and thus 
activate them (15). Evidence is steadily ac-
cumulating in support of the concept that 
these and other inflammasomes are key ini-
tiators of immune responses, and most likely 
to be involved in processes governing the 
selection between activation (immunogenic-
ity, inflammatory response) and inhibition 
(tolerogenicity), the latter being crucial to 
immune (and overall) homeostasis. RLR are 
somewhat less studied than TLR and NLR. It 
is known that these PRR detect viral replica-
tion by binding dsRNA in the cytoplasm of 
infected cells (16).
Cells expressing PRR
The central elements in the conveyance of in-
formation from innate to adaptive immune 
systems are antigen-presenting cells (APC) 
(17). They have the potential to uptake an-
tigens, process them into small peptides and 
load them onto major histocompatibility 
complex (MHC) class II molecules for pre-
sentation to T cells. Upon activation, APC 
upregulate MHC class II, as well as costimu-
latory molecules (e.g. CD80 and CD86) that 
provide “signal 2”, which is necessary for full 
activation of T cells. This second signal as-
sures that only APC that are activated by dan-
ger signals can trigger T cell response (18). 
The principal APC are dendritic cells (DC). 
DC are most potent in activating naïve T 
cells and cross-presenting exogenous antigens 
through MHC class I pathway to cytotoxic 
T lymphocytes (CTL). In addition to DC, 
APC include macrophages, B lymphocytes, 
activated endothelial and some epithelial 
cells, as well as some other cell types under 
certain conditions (19). However, most of 
these cells lack the full set of costimulatory 
molecules required to induce the full spec-
trum of T cell responses. Apart from APC, 
there are also several cell types not usually in-
volved in antigen-presentation that neverthe-
less express PRR and thus may contribute to 
immune responses elicited by adjuvants (20). 
The exact roles of these cell types in immune 
responses are still a subject of research.
Mechanisms of action of adjuvants
Among the first acknowledged mechanisms 
of adjuvant action are depot effect and an-
tigen delivery. Aluminium salts were con-
sidered to function by formation of a depot 
from which the antigen is slowly released. 
This was disputed in several studies showing 
that adsorption to aluminium salts does not 
increase significantly the half-life of antigen 
in vivo (21). However, by converting soluble 
antigen into a particulate form, aluminium 
adsorption increases antigen uptake by APC, 
and thus acts as an atigen delivery system. 
Other adjuvants, classified as delivery sys-
tems (liposomes, immune-stimulating com-
plexes, nanoparticles) also function primarily 
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as vehicles to deliver antigens to particular 
cells or cellular compartments (22).
The most general mechanism of adjuvan-
ticity is recruitment of inflammatory cells 
and establishment of a local immunocompe-
tent environment (20). Virtually all adjuvants 
induce some level of inflammatory reaction 
with secretion of proinflammatory cytokines 
and chemokines, thus recruiting and activat-
ing inflammatory cells. This is the central 
mechanisms of action of emulsions and min-
eral salts (23). Cells that are damaged in this 
inflammatory process release DAMP that ac-
tivate APC and other inflammatory cells.
It is now well established that aluminium 
salts directly activate NLRP3, member of 
NLR family, which leads to the formation of 
inflammasome, and subsequent processing 
and release of proinflammatory cytokines IL-
1β, IL-18 and IL-33 (24). The same mecha-
nism is demonstrated for some other particu-
late adjuvants (25). This process is also acti-
vated by some DAMP molecules, like ATP, 
uric acid and monosodium urate crystals. It 
is postulated that aluminium salts, in addi-
tion to direct activation of NLRP3, indirectly 
activate this pathway by releasing uric acid 
from necrotic cells (26).
Some adjuvants consist of microbial com-
ponents or their analogues, and target APC 
and other inflammatory cells by directly acti-
vating TLR and other PRR (7). Activation of 
APC, more specifically DC, either directly or 
indirectly, is the central event in the mecha-
nism of action of most adjuvants (7, 20, 27). 
Activation of DC leads to the upregulation 
of cytokines, chemokine receptors, MHC 
class II, and costimulatory molecules, and to 
their migration to the T cell zone of regional 
lymph nodes, where they present antigens 
they have sampled to naïve T cells, thus ac-
tivating them and initiating the adaptive im-
mune response.
The main classes of adjuvants in use
Mineral salts
By far the most extensively used vaccine adju-
vants today, as has been the case throughout 
the history of adjuvant use, are aluminium 
salts. Mod ern human vaccines use pre-formed 
aluminium gels containing sulfate, phosphate 
or hydroxide salts of aluminum, but compo-
sition and higher order structure of different 
formulations varies considerably (8, 22). For 
some proprietary aluminum salt adjuvants, 
the full chemical formula and process of for-
mulation are not publicly available. Frequent-
ly, term “alum” is wrongly used as a catch-all 
term for aluminum salt-containing adjuvants. 
Alum is chemically defined as hydrated potas-
sium aluminum sulfate (KAl2(SO4)2·12H2O), 
and it has been used as a reagent in the process 
of preparing aluminium-based adjuvants, not 
as an adjuvant per se (28). It is important to 
acknowledge that surface chemistry, particle 
size, and structure are important attributes of 
aluminium gels that influence their properties 
as adjuvants (29). Aluminium hydroxide and 
aluminium phosphate have opposite electrical 
charges at neutral pH. Hence, it is important 
to carefully select the type of aluminium ad-
juvant and optimize the conditions of adsorp-
tion for each antigen. By simply changing the 
surface chemistry of aluminium gels by the 
addition of a defined amount of phosphate or 
hydroxyl ions, it is possible to alter antigen-
binding affinity, stability and potency. The 
size of particles also influences how innate im-
munity will react, and the effect can vary from 
no proinflammatory response, to functional 
adjuvanticity, to frustrated phagocytosis (8). 
With almost a century of experience, 
aluminum salt adjuvants have demonstrated 
effective induction of relatively long-lasting 
protective immunity to extracellular patho-
gens, ease of formulation, and a long record 
of general safety (30). They elicit strong Th2 
polarization and induce high IgG titers. On 
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the other hand, aluminium salts do not stim-
ulate cell-mediated cytotoxic CD8+ T cell 
response, which is necessary for protection 
against viruses and other intracellular patho-
gens (27, 30).
Emulsions
Another classical adjuvant, complete Freund’s 
adjuvant (CFA), discovered by Jules Freund 
in 1951, is an emulsion of soluble antigen in 
paraffin oil (water-in-oil emulsion), with a 
surfactant and inactivated dry Mycobacteria. 
Because of its high potency, it was long used 
for induction of immune response in experi-
mental settings, but it was too toxic for use in 
humans. A less potent variant, and easier for 
preparation and application, is oil-in-water 
emulsion called incomplete Freund’s adju-
vant (IFA), for it does not contain Mycobac-
teria. However, it is still too reactogenic to be 
used in human vaccines (7).
There are now two licensed oil-in-water 
emulsion adjuvants for use in human vac-
cines – MF59 (Novartis) and AS03 (GlaxoS-
mithKline). They are both based on squalene 
as the oil component. Squalene is a biode-
gradable oil extracted from shark liver, which 
is also naturally found in human tissues. In 
addition, MF59 contains surfactants, poly-
oxyethylene sorbitan mono-oleate (Tween 
80) and sorbitan trioleate, and AS03 con-
tains Tween 80 and α-tocopherol (vitamin 
E). They are used in seasonal and pandemic 
flu vaccines, since they elicit a high titer of 
neutralizing antibodies, as well as a strong 
CD8+ T cell response. Both emulsions have 
good safety records (see below), permit fewer 
doses and antigen dose sparing, and gener-
ate marked memory responses, with a mixed 
Th1 and Th2 cell phenotypes (31).
TLR-agonists
Since the discovery of TLR and their fun-
damental role in innate immunity, much of 
the effort is directed towards development 
of adjuvants that would directly target these 
PRR. Up to now, only one TLR agonist adju-
vant has been licensed, but many are in some 
phase of preclinical research or clinical trials. 
Monophosphoryl lipid A (MPL) is a deriva-
tive of LPS, a TLR4 agonist, but it is 10,000 
times better tolerated than the original lipid 
A (2, 32). Adhered to aluminum salt in AS04 
combined adjuvant, it is currently approved 
for use in one of the vaccines against human 
papilomavirus (Cervarix®). It has been shown 
to be able to increase antibody titers and to 
induce a strong cellular immune response.
Synthetic analogues of bacterial and vi-
ral nucleic acids are also promising candi-
dates for adjuvants. Synthetic 5’-cytosine-
phosphate-guanine-3’ oligodeoxynucelotides 
(CpG-ODN) that contain unmethylated 
CpG, characteristic for bacterial DNA, are 
ligands for TLR9. CpG-ODN enhance an-
tibody responses and strongly polarize Th 
cell responses towards Th1 and away from 
Th2 (33). Another synthetic analogue of 
nucleic acid, polyinosinic:policytydilic acid 
(poly I:C), has a structure similar to dsRNA, 
which is unique to some viruses. This ana-
logue binds two types of PRR – TLR3 and 
MDA5 (a RLR). Activation of both receptors 
optimizes the magnitude and durability of 
Th1 cell immunity and CD8+ T cell immu-
nity compared to either pathway alone (34).
Usual ligands for TLR7 and TLR8 are 
guanosine- and uridine-rich ssRNA. Howev-
er, ssRNA is very unstable, so other synthetic 
agonists are used to stimulate these receptors, 
such as imiquimod and resiquimod (35). Ad-
juvanticity of these small molecules is sub-
stantially improved when they are coupled 
to an antigen, compared to when they are 
simply admixed. Bacterial flagellin, a TLR5 
agonist, can also be used as an adjuvant, ei-
ther in a mixture with an antigen or when 
fused with it as a single recombinant protein 
(36). Unlike much of the other TLR agonists 
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that strongly polarize Th1 cell response, fla-
gellin tends to produce mixed Th1 and Th2 
cell responses.
Delivery systems
Special form of vaccine/adjuvant formula-
tions are delivery systems. Their function is 
to deliver the antigen into an APC for en-
hanced processing and presentation. Deliv-
ery systems can incorporate in their structure 
some of the previously mentioned adjuvants. 
They include liposomes, immune-stimulat-
ing complexes and nanoparticles (22).
Liposomes are bilayered or multilayered 
biodegradable vesicles, made of phospholipids 
that mimic the structure of natural lipid bilayer 
membranes, enabling them to enter APC by 
endocytosis. They are able to carry insoluble 
antigens and considerably enhance the im-
munogenicity of weakly immunogenic protein 
antigens (37). Immune-stimulating complexes 
(ISCOM) are proprietary forms of liposomes 
made of phospholipids, cholesterol, and sapo-
nins from the bark of Quillaja saponaria, that 
form cage-like structures (ISCOMATRIX) 
into which antigens can be entrapped or inter-
calated (38). They can provide a depot func-
tion, as well as facilitated delivery, uptake, and 
processing of vaccine antigens by APC.
Application of nanotechnology for de-
signing carrier systems for antigen delivery is 
a new and perspective area of vaccine devel-
opment (2). These nanovaccines can vary in 
size, shape, composition, and surface prop-
erties, and can be customized to modulate 
antigen processing and presentation path-
ways according to specific needs. Rationally 
developed nanovaccines are one of the most 
promising candidates for the future of vac-
cine development.
Safety of adjuvants
Since adjuvants, by definition, are always ad-
ministered as a part of a vaccine, and are eval-
uated as such, the first challenge in assessing 
adverse reaction to adjuvants is to separate 
them from reactions to other vaccine com-
ponents (39). Bearing in mind that vaccines 
are generally administered to healthy people, 
including vulnerable populations such as 
children and pregnant women, vaccines must 
meet much higher safety standards than other 
medicines. As with other medicines, vaccines 
also have to pass three phases of clinical stud-
ies, where safety and efficacy of the vaccine 
is evaluated on progressively larger and more 
diverse populations. In order to obtain licen-
sure, a new vaccine has to prove to have a 
good benefit-to-risk ratio, that is, to demon-
strate that its expected benefits in preventing 
disease clearly outweighs any potential risk to 
the targeted population. After the licensure, 
the safety and benefit-to-risk assessments 
continue indefinitely. Whenever the evidence 
of causal association between the vaccine and 
adverse event arise, or the vaccine eventually 
shows poor efficacy, the benefit-to-risk ratio 
decreases and the vaccine may be withdrawn.
In view of the discussed roles of adjuvants 
as immune potentiators, it is not without 
grounds to presume that adjuvants in vac-
cines can also provoke an undesirable im-
mune response. Indeed, many adverse events 
of vaccines can be attributed to adjuvants and 
their mechanisms of action (40). Adjuvants 
are generally considered principally respon-
sible for the usual mild to moderate vaccine 
reactions (redness and swelling at the injec-
tion site, low-grade fever, fatigue, myalgia, 
headache), since these reactions are mostly 
caused by the activation of innate immunity, 
with brief release of inflammatory mediators. 
More serious adverse reactions to adjuvants 
have been repeatedly found to be rare (30, 
31, 41, 42). However, some adjuvants have 
tentatively been linked to pathological con-




During the 2009 H1N1 influenza pandemic 
in some European countries a number of 
cases of narcolepsy were reported following 
vaccination with Pandemrix®, a GlaxoSmith-
Kline’s pandemic influenza vaccine (H1N1 
2009), containing AS03 as adjuvant (43). 
Narcolepsy is a chronic neurological disor-
der presenting with excessive daytime sleepi-
ness and often cataplexy – a transient loss of 
muscle tone triggered by strong emotional 
stimuli. It is characterized by loss of hypo-
thalamic hypocretin-producing neurons, 
and is strongly associated with the HLA-
DQB1*0602 genotype. At the same time, no 
association with narcolepsy has been report-
ed for another similar pandemic flu vaccine, 
Novartis’ MF59-adjuvanted Focetria®. This 
fact has brought into focus the role of H1N1 
viral proteins or the AS03 adjuvant as envi-
ronmental triggers in genetically predisposed 
persons. It was proposed that α-tocopherol, 
the specific component of AS03, via tran-
scription factor Nrf2, affects the expression 
and turnover of hypocretin, leading to an 
increased formation of longer hypocretin-
derived fragments that can be presented by 
HLA-subtype DQB1*0602 (44). Another 
study, however, suggested a different mecha-
nism (45). It demonstrated increased fre-
quency of antibodies to hypocretin receptor 
2 in the sera of narcoleptic patients with a 
history of immunization by Pandemrix®, 
which cross-reacted with a fragment of in-
fluenza nucleoprotein A that was found in 
Pandemrix® vaccine in much greater amount 
than in other related pandemic vaccines. This 
antigen-mimicry may also explain the asso-
ciation of cases of narcolepsy with seasonal 
influenza infections (46). Considering all the 
data collected from epidemiological studies, 
as well as experimental research of immuno-
logical basis of pandemic influenza vaccine-
induced narcolepsy, European Medicines 
Agency has concluded that the benefit-risk 
profile of H1N1 2009/AS03 remains favor-
able (although “the marketing authorization 
for Pandemrix® has expired following the 
marketing-authorization holder’s decision 
not to apply for a renewal” in 2016) (47).
Macrophagic myofasciitis
Macrophagic myofasciitis (MMF) represents 
a histological lesion containing aluminium 
crystal-laden macrophages gathered around 
the muscular fibers, found at the injection 
site of aluminium-adjuvanted vaccines for a 
very long time after vaccination (48). A caus-
al association of these lesions with a group of 
systemic manifestations that includes myal-
gias, arthralgias, asthenia, muscle weakness, 
chronic fatigue, and fever, was proposed to 
represent a distinct immune-mediated condi-
tion triggered by aluminum-containing vac-
cines in genetically susceptible people (49). 
Some studies suggested that increased level 
of CCL2 chemokine present in patients with 
this condition is associated with an impaired 
capacity to excrete aluminium, which could 
provide a biological explanation for suscep-
tibility of some individuals to aluminium-
based adjuvants (50). Although this finding 
certainly merits further investigation, conclu-
sive evidence of a link between aluminium 
adjuvant-containing vaccines or MMF lesion 
and systemic muscular disease is still missing, 
and WHO Global Advisory Committee on 
Vaccine Safety states that there is no reason 
to conclude that a health risk exists as a result 
of administration of aluminium containing 
vaccines (51).
Squalene and the Gulf War Syndrome
One of more controversial associations of 
vaccine adjuvants with an illness is the alle-
gation that squalene is a causative agent of a 
group of nonspecific systemic symptoms that 
occurred in veterans of the 1991 Persian Gulf 
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War, known as Gulf War syndrome (GWS). 
The syndrome encompasses various physi-
cal, psychical, and cognitive symptoms, and 
clinically overlaps with post-traumatic stress 
disorder, chronic fatigue syndrome, fibromy-
algia, and other functional disorders. Since 
the soldiers had been exposed to unique 
hazardous environmental conditions, many 
causal factors have been proposed, including 
vaccinations (52). One study showed a con-
nection between the anti-squalene antibod-
ies and GWS (53). Squalene-based adjuvant 
was allegedly used in antrax vaccine that was 
administered to the soldiers, and antibodies 
to squalene were detected in the sera of most 
patients affected. However, the initial conclu-
sion was refuted by later studies that found 
no association between squalene antibody 
status and chronic multisymptomatic illness, 
and showed that squalene was not even pres-
ent in vaccines administered to these soldiers 
(54). Additionally, squalene per se is poorly 
immunogenic, it is widespread in nature, 
even produced in human liver and skin, and 
low titers of anti-squalene antibodies are rou-
tinely found in healthy individuals, and their 




Many more immune-mediated diseases and 
conditions are occasionally reported to be 
associated with adjuvants and vaccines as a 
whole (56). As a way of grouping together 
a range of emerging autoimmune diseases 
with possible adjuvant-associated causes, Ye-
huda Shoenfeld and Nancy Agmon-Levin 
proposed a new syndrome – Autoimmune/
Inflammatory Syndrome Induced by Adju-
vants (ASIA), also known as Shoenfeld’s syn-
drome (57). In a systematic review published 
in 2015, Hawkes et al. questioned the clini-
cal value of ASIA, as its diagnostic criteria are 
very broad and lack a precise definition of 
temporal association and dosage limits, but 
recognized that it provides a framework facil-
itating the investigation of rare and unusual 
cases of potential vaccine/adjuvant-induced 
autoimmunity (58). 
The occurrence of these rare adverse re-
actions should by no means hamper further 
development of new adjuvants or imply that 
it may be safer not to vaccinate, foregoing 
protection offered by vaccines. The positive 
effect on reduction of infectious disease mor-
bidity and mortality, by far exceeds the nega-
tive side effects of vaccination. Moreover, 
one must not overlook the fact that vaccines 
only mimic natural infections, and infectious 
agents themselves can elicit the same immune 
phenomena. Indeed, the risk of develop-
ing immune-mediated diseases by acquiring 
natural infection is even greater than the risk 
of the same diseases to develop by vaccine-
associated reactions. By carefully monitor-
ing the rare adverse events and scrupulously 
studying their mechanism of development, 
regulatory agencies, vaccine manufacturers, 
and researchers are participating in a joint 
endeavor to identify the specific factors that 
contribute to these events and to develop 
even safer vaccines. 
Conclusion
Adjuvants are an extremely important class 
of vaccine components. Their use allows a 
great variety of vaccine designs, enabling the 
development of safe and effective vaccines to 
protect from many conditions that would 
otherwise be impossible to create. Although, 
as vaccines themselves, adjuvants are not risk-
free in an absolute sense, they have actually 
made vaccination safer as well as more effec-
tive, since adjuvanted vaccines can often be 
more finely tuned to specific needs of elicit-
ing an immune response against a particular 
pathogen, as well as optimized beyond the 
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level possible without adjuvants, including 
the possibility to restrict the number of an-
tigens present in a vaccine, and thus further 
reduce any risk of undesired (cross-reactive) 
immune responses to self tissues. Adjuvants 
can also increase the cost-effectiveness and 
simplify the logistics of vaccine use. Despite 
frequent calls to debate, all currently used 
adjuvants have repeatedly demonstrated an 
excellent safety profile, and remain, together 
with the vaccines they are part of, one of the 
principal tools of science-based medicine in 
preventing infectious diseases that have cost 
mankind many lives in the past, and are still 
threatening to do so wherever and whenever 
vaccination efforts fall below adequacy.
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